Description and validation of a Markov model of survival for individuals free of cardiovascular disease that uses Framingham risk factors
<p>Abstract</p> <p>Background</p> <p>Estimation of cardiovascular disease risk is increasingly used to inform decisions on interventions, such as the use of antihypertensives and statins, or to communicate the risks of smoking. Crude 10-year cardiovascular disease risk...
Main Authors: | Martin Chris, Vanderpump Mark, French Joyce |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2004-05-01
|
Series: | BMC Medical Informatics and Decision Making |
Online Access: | http://www.biomedcentral.com/1472-6947/4/6 |
Similar Items
-
Validation and recalibration of the Framingham cardiovascular disease risk models in an Australian Indigenous cohort.
by: Hua, X, et al.
Published: (2017) -
Framingham cardiovascular risk in patients with obesity and periodontitis
by: Juliana Rico Pires, et al.
Published: (2014-01-01) -
Framingham score in the evaluation of cardiovascular risk in diabetics
by: Mariana Costa Larré, et al.
Published: (2015-02-01) -
Framingham risk prediction equations for incidence of cardiovascular disease using detailed measures for smoking
by: John McNeil, et al.
Published: (2010-09-01) -
Prediction of cardiovascular risk using Framingham, ASSIGN and QRISK2: how well do they predict individual rather than population risk?
by: Tjeerd-Pieter van Staa, et al.
Published: (2014-01-01)